Farid El Hajbi

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial

Thierry Conroy, Jean-François Bosset, Pierre-Luc Etienne et al. · The Lancet Oncology · 2021 · 1.2K citations

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

Yuichiro� Doki, Jaffer A. Ajani, Ken Kato et al. · UCL Discovery (University College London) · 2022 · 532 citations · Full text

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study

Stéfano Kim, Éric François, Thierry André et al. · The Lancet Oncology · 2018 · 140 citations

Gastrointestinal Oncology, Medicine, Metronomic Therapy +6

Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.

Ian Chau, Yuichiro� Doki, Jaffer A. Ajani et al. · Journal of Clinical Oncology · 2021 · 110 citations

Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial

Pascal Hammel, Fabienne Portales, Laurent Mineur et al. · European Journal of Cancer · 2019 · 106 citations · Full text